Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human HER2 ELISA Kit for Sandwich ELISA - ABIN921095
Tao, Suhua, Juanjuan, Zongzhi, Juan, Dandan: In vitro study on human cytomegalovirus affecting early pregnancy villous EVT's invasion function. in Virology journal 2011
Human HER2 ELISA Kit for Sandwich ELISA - ABIN625296
Laidi, Bouziane, Lakhdar, Khabouze, Rhrab, Zaoui: Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. in OncoTargets and therapy 2014
Tumor infiltrating lymphocytes cannot be used as a prognostic biomarker in pT1a-b HER2-positive breast cancer.
Data suggest ESE-1 (show ELF3 ELISA Kits) silencing as a mean to treat HER2(+) patients who show resistance to anti-HER2 therapy.
Data show that HER2 breast cancer patients with good performance status, controlled extracranial (EC) metastasis and single brain metastasis (BM) had better outcome.
In this review the information regarding various epigenetic markers implicated in HER2 positive breast cancer susceptibility and therapeutic-strategies has been compiled. [review]
NRG1 (show NRG1 ELISA Kits)/ErbB2/Src (show SRC ELISA Kits)/PTK2 (show PTK2 ELISA Kits) signaling pathway may be a novel regulator of keloid fibroblast migration.
Patients with triple-negative breast cancer have an increased serum HER2 concentration, and serum HER2 may be a valuable, novel biomarker for recurrence and metastasis in TNBC.
Overexpression of HER-2 is a simple and reliable predictor for increased recurrence and poorer survival in patients with T3-gastric adenocarcinoma following surgical resection.
we found an association of PD-L1 (show CD274 ELISA Kits) with luminal cancers in our cohort. Despite its association with less aggressive cancer subtype, an independent poor prognostic impact of PD-L1 (show CD274 ELISA Kits) in HER2-positive breast cancers was observed.
Gastric cancer HER2 positivity was associated with lower median overall survival in Sri (show SRI ELISA Kits) Lankan patients.
HER2 overexpression or activation was detected by the PRO Onc assay in 22 % of HER2-negative patients with CTCs. However, HER2-targeted therapy was not effective in such patients. FISH and IHC staining remain the standards for HER2 determination.
Results indicate the importance of the LDL receptor (LDLR (show LDLR ELISA Kits)) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110alpha (show PIK3CA ELISA Kits) to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha (show PIK3CA ELISA Kits) inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB (show NUMB ELISA Kits) and NUMBL (show NUMBL ELISA Kits) interacted with small GTPase (show RACGAP1 ELISA Kits) Rab7 (show RAB7A ELISA Kits) to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta (show TGFB1 ELISA Kits), EGFR (show EGFR ELISA Kits) and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR (show EGFR ELISA Kits)-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB (show EGFR ELISA Kits) receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS (show IARS ELISA Kits) pathway in mouse breast cancer model.
It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis
Newly synthesized N-cadherin (show CDH2 ELISA Kits) molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 (show NRG1 ELISA Kits) is not the primary effector of trabeculation and/or that other EGF (show EGF ELISA Kits)-like ligand(s) activates the ErbB2/ErbB4 (show ERBB4 ELISA Kits) pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF (show EGF ELISA Kits) family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT (show AKT1 ELISA Kits) signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 (show ERBB3 ELISA Kits) and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 (show NRG1 ELISA Kits) and PI3K functionally interact with ErbB2 and ErbB3 (show ERBB3 ELISA Kits) during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR (show EGFR ELISA Kits)) and human epidermal growth factor receptor (show EGFR ELISA Kits) 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2